SUTIMLIMAB-JOME INJ,SOLN
Clinical Criteria Summary
Indication
- Classical complement inhibitor indicated to decrease the need for red blood cell (RBC) transfusions due to hemolysis with cold agglutinin disease (CAD).
Patient Selection/Clinical Criteria
- Confirmed CAD diagnosis.
- Hemoglobin ≤10 g/dL.
- Total bilirubin above normal reference range.
- Ferritin level above the lower limit of normal.
- One or more symptoms: symptomatic anemia, acrocyanosis, Raynaud’s phenomenon, hemoglobinuria, disabling circulatory symptoms, or major adverse vascular event including thrombosis.
- Documented vaccinations against encapsulated bacterial pathogens within 5 years of enrollment.
Exclusion Criteria
- Cold agglutinin syndrome secondary to infection, rheumatologic disease, or active hematologic malignancy.
- History of blood transfusion within 6 months or >1 transfusion within 12 months.
- Systemic lupus or other autoimmune disorder.
- Erythropoietin deficiency.
- Clinically relevant infection.
- Recent rituximab use (within 3 months) or rituximab combination therapy (within 6 months).
- Concurrent corticosteroid treatment other than a stable daily dose equivalent to ≤10 mg/d prednisone.
Dosing & Administration
- Administered intravenously over 1 hour on Day 0 and Day 7, then every 2 weeks up to 26 weeks.
- Dose based on weight: <75 kg: 6500 mg in 500 mL; ≥75 kg: 7500 mg in 500 mL.
- Infusion may be extended to 2 hours if patient has underlying cardiopulmonary disease.
Safety & Monitoring Requirements
- Contraindicated in patients with known hypersensitivity to sutimlimab-jome or any inactive ingredients.
- Vaccinate/revaccinate for encapsulated organisms per ACIP recommendations at least 2 weeks prior to first infusion unless urgent; vaccinate ASAP if unvaccinated.
- Monitor for serious infections caused by encapsulated bacteria (e.g., Neisseria meningitidis, Streptococcus pneumoniae, H. influenzae); monitor active systemic reactions and consider dose interruption.
- Not studied in patients with chronic systemic infections (hepatitis B, hepatitis C, or HIV).
- Interrupt infusion for infusion-related reactions; discontinue therapy and provide supportive care if signs of hypersensitivity occur (cardiovascular instability, respiratory compromise).
- Monitor for risk of autoimmune diseases (e.g., systemic lupus erythematosus) based on mechanism of action.
- Following treatment interruption, monitor for recurrent hemolysis (↑total bilirubin or LDH, ↓hemoglobin) and symptom reappearance (fatigue, dyspnea, palpitations, hemoglobinuria); consider restarting therapy if recurrent hemolysis occurs.
Place in Therapy Considerations
- First FDA-approved drug for CAD; complement-directed therapies likely required for lifetime or until disease progression.
- May be considered following B-cell directed therapies (rituximab or bendamustine/rituximab) if patient is fit for immunochemotherapy.